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Abstract We present the first two reported unrelated patients
with an isolated sedoheptulokinase (SHPK) deficiency. The
first patient presented with neonatal cholestasis, hypoglyce-
mia, and anemia, while the second patient presented with con-
genital arthrogryposis multiplex, multiple contractures, and
dysmorphisms. Both patients had elevated excretion of
erythritol and sedoheptulose, and each had a homozygous
nonsense mutation in SHPK. SHPK is an enzyme that phos-
phorylates sedoheptulose to sedoheptulose-7-phosphate,
which is an important intermediate of the pentose phosphate
pathway. It is questionable whether SHPK deficiency is a
causal factor for the clinical phenotypes of our patients. This
study illustrates the necessity of extensive functional and clin-
ical workup for interpreting a novel variant, including non-
sense variants.
Introduction
Sedoheptulokinase (SHPK; EC 2.7.1.14), formerly known as
carbohydrate-kinase-like (CARKL), is an enzyme that phos-
phorylates sedoheptulose to sedoheptulose-7-phosphate
(sedoheptulose-7P) (Touchman et al 2000; Wamelink et al
2008; Kardon et al 2008; Haschemi et al 2012). SHPK is
highly expressed in liver, kidney, pancreas, and heart tissue.
Sedoheptulose-7P is an important intermediate of the pentose
phosphate pathway (PPP), a key pathway of carbohydrate
metabolism. The PPP and glycolysis are tightly connected:
The PPP is located in the cytosol and is primarily responsible
for the production of cytosolic nicotinamide adenine dinucle-
otide phosphate, reduced (NADPH) and ribose-5P. The SHPK
protein co-localizes with glucose-6P dehydrogenase in the
cytoplasm (Haschemi et al 2012). SHPK seems to be an im-
portant regulatory enzyme, being responsible for feeding
sedoheptulose-7P molecules to the PPP independently of glu-
cose. Effectively, this allows the reversible function of
transaldolase (TALDO) and/or transketolase when glyceralde-
hyde-3-phosphate, arising from the glycolytic pathway, is
used by the PPP, when increased amounts of NADPH and/or
ribose moieties are needed for nucleotide production
(Wamelink et al 2008; Nagy and Haschemi 2013). Free
sedoheptulose can be either derived dietarily from fruits and
vegetables (Kardon et al 2008) or formed enzymatically by
dephosphorylation from sedoheptulose-7P or possibly from
other heptoses, such as mannoheptulose or 7-O-galloyl-
sedoheptulose. To date, no specific sedoheptulose-7P phos-
phatase has been reported.
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Knockdown of SHPK in a mouse macrophage cell line
resulted in increased glyceraldehyde-3P, xylulose-5P, and
ribose-5P intracellular levels. Sedoheptulose concentrations
were not notably changed, while sedoheptulose-7P was sig-
nificantly decreased (Haschemi et al 2012), which resulted in
rerouting of glucose from aerobic to anaerobic metabolism
and was accompanied by a decreased nicotinamide adenine
dinucleotide (NAD)/NADH ratio. In the same cell line, the
opposite was found by overexpressed SHPK, although
sedoheptulose-7P concentrations remained normal. In a
screen for new regulators of macrophage activation, over-
expression of SHPK was found to block lipopolysaccha-
ride (LPS)-induced tumor necrosis factor alpha (TNFα)
secretion by these cells (Haschemi et al 2012). In vitro
and in vivo, SHPK transcript is endogenously downregu-
lated in mice and humans during LPS-induced inflamma-
tion. In vitro, knockdown of the gene by micro-RNA-
adapted short hairpin RNA (shRNA-mir) results in mild
activation of macrophages. This indicates that SHPK-
dependent metabolic reprogramming is required for proper
M1- and M2-like macrophage polarization and is a rate-
limiting requirement for appropriate glucose flux during
macrophage polarization (Haschemi et al 2012).
So far, SHPK deficiency has not been described in humans
as an isolated defect and is only known as a combined defect,
with cystinosis caused by a 57-kb deletion extending from
exon 10 of CTNS (cystinosin, lysosomal cystine transporter),
upstream through SHPK/CARKL, to intron 2 of TRPV1 (tran-
sient receptor potential vanilloid 1) (Touchman et al 2000;
Freed et al 2011). Patients with this deletion have the infantile
nephropathic cystinosis type (MIM 219800), but the clinical
relevance of SHPK deficiency remains unclear. In urine of
these patients, high concentrations of sedoheptulose and
erythritol are detected, and in bloodspots, sedoheptulose is
also elevated compared with controls or patients with isolated
cystinosis (Wamelink et al 2008, 2011).
We diagnosed two unrelated patients with isolated SHPK
deficiency caused by different nonsense mutations in SHPK.
Materials and methods
Patients
Patient 1, a boy (currently 3 years old), was born after
35 weeks’ gestation from a healthy Caucasian mother and
unknown father (suspected consanguineous relationship).
The infant presented with perinatal asphyxia, birth weight of
1,750 g (P2.3–P5), craniofacial dysmorphisms (high forehead
with very large fontanels, hypotelorism, and small orbits),
unilateral inguinal hernia, and a sepsis-like condition with
intestinal pseudoobstruction, transient hypoglycemia, chole-
static hepatitis, and transient renal failure (maximum plasma
creatinine 132 μmol/L and urea 11 mmol/L at day 5 of life,
which normalized on day 10). He has chronic diarrhea, with
steatorrhea and severe growth retardation including short stat-
ure and macrocephaly (relative to stature). Frequent, mostly
asymptomatic, short-fasting hypoglycemic episodes (with
normal lactate and ketones) and postprandial hyperglycemia
aggravated by the end of the first year of life persist in spite of
frequent meals. Transient hypocortisolism was identified, but
hypoglycemia did not respond to specific treatment. He is
currently under exocrine pancreatic yeast supplementation.
He has moderate intellectual disability and neurosensorial
deafness. He needed several blood transfusions due to chronic
microcytic hypochromic anemia, with normal ferritin,
leucocytes, and platelets. Because of childhood infections
(bronchiolitis and middle ear infections with febrile
rhinopharyngitis), inpatient admission was needed due to dif-
ficulty in glycemic control; immune system deficiency was
ruled out. His abdominal skin is strikingly thin, with upper
collateral circulation and diastasis recti without liver or spleen
enlargement.
Brain magnetic resonance imaging (MRI) was normal in
the neonatal period. At the age of 3 years, MRI showed ven-
tricular enlargement, cerebral subcortical atrophy, hyperin-
tense periventricular lesions, hypomyelinization, and a
Chiari malformation type 1 (Fig. 1).
A broad etiological investigation including peroxisomal
function, carbohydrate-deficient transferrin, acylcarnitine pro-
file, urinary organic acids, microarray comparative genomic
hybridization (CGH) and UBR1, SBDS, and COX412 genes
has been inconclusive. At the age of 20 months, during a
metabolic workup, elevated urinary concentrations were
found for erythritol and sedoheptulose with gas chromatogra-
phy mass spectrometry (GC-MS). His immune system was
evaluated. Immunoglobulin (Ig) G, A, M, and E levels were
normal; leucocyte number and distribution and lymphocyte
populations T, B, and NK were investigated; an inverted
CD4/CD8 and low CD19 and CD56 were found but were
not considered relevant. In the lymphoblast transformation
test, there was a normal proliferative response to the mitogens
phytohemagglutinin(PHA), pokeweed mitogen (PWM), and
staphylococcal protein A (SPA).
Patient 2, a girl (currently 2 years old), second child of
healthy consanguineous parents from Turkish heritage, was
born at term. External cephalic version was successfully per-
formed antenatally because of breech presentation. She pre-
sented at birth with perinatal asphyxia, birth weight of 2,580 g
(P2.3–P5), congenital arthrogryposis multiplex, hip dysplasia,
and numerous contractures. She has multiple dysmorphisms:
round, asymmetrical eyes (right eye larger) with ptosis and
Bells phenomenon; small mouth; high nasal bridge; dysplastic
low-set ears, most prominent on the right; adducted thumbs;
strikingly smooth palms; and small feet. From birth, she has
had enormous feeding problems due to unsafe swallowing.
890 J Inherit Metab Dis (2015) 38:889–894
Developmentally, she makes good contact but has impair-
ments at all domains.
At the age of 7 days, her metabolic screening showed
strongly elevated erythritol and sedoheptulose (GC-MS).
MRI of the brain at 7 months showed no abnormalities, with
symmetrical slim ventricles. Her immune system was evalu-
ated: white blood cell differentiation, total IgA, total IgM, total
IgG, and subclasses were all normal. She has not suffered
from infections and is growing well. Genetic screening (array,
targeted next-generation sequencing for intellectual disability)
showed no abnormalities, but there is a homozygous nonsense
mutation in SHPK.
Analysis of erythritol, sedoheptulose, and sedoheptulose-7P
in urine
Erythritol, sedoheptulose, and sedoheptulose-7P were quanti-
fied in urine of both patients by liquid chromatography tan-
dem mass spectrometry (LC-MS/MS), as described
(Wamelink et al 2005a, 2007).
Molecular analysis of SHPK and TALDO1
SHPK, GenBank accession number NM_013276.2, is
mapped to chromosome 17. The exons, including splice sites,
were amplified by polymerase chain reaction (PCR). The
open-reading frame (ORF) of SHPK and splice sites have
been analyzed by DNA sequence analysis. All seven exons
and adjacent splice sites of the SHPK gene of both patients
were amplified by PCR and analyzed by direct DNA sequence
analysis (for primers, see Supplementary Table 1). DNA of
both patients’ mothers and one father (of patient 2) was only
investigated for the amplicon containing the familial mutation.
Amplicons were analyzed by capillary electrophoresis using
an ABI 3130xl genetic analyzer (Applied Biosystems,
Nieuwerkerk a/d lJssel, The Netherlands) and assessed using
Mutation Surveyor® (Softgenetics, PA, USA). In addition to
the genomic DNA (gDNA) analysis, we also investigated the
SHPK transcript. RNA was isolated from PAXgene blood
RNA tub e s (Q IAGEN , Ben e l u x B .V. , Ve n l o ,
The Netherlands) of patient 1 and his mother; complementary
DNA (cDNA) was synthesized, and subsequently, the full-
length ORF was amplified. These amplicons were directly
sequenced, as described above. The reference sequence
NM_013276.2 was used, and the A of the ATG translation
initiation codon is nucleotide 1 following guidelines of the
Human Genome Variation Society (www.hgvs.org/
mutnomen).
Mutation analysis of transaldolase (TALDO1, GenBank ac-
cession number NM_006755.1) was performed in patient 1 by
direct sequence analysis of genomic DNA (gDNA), basically
as described previously (Verhoeven et al 2001).
Analysis of SHPK activity in fibroblasts
To assay SHPK activity, fibroblast homogenates from patient
1 and simultaneously two control fibroblast homogenates
were incubated with sedoheptulose and adenosine
triphosphate (ATP). Incubation was performed as described
earl ier (Wamelink et al 2008). After incubation,
sedoheptulose-7P formation was analyzed, as described
(Wamelink et al 2005b) using a calibration curve of
sedoheptulose-7P (Sigma-Aldrich, St Louis, MO, USA).
SHPK Western blot analysis
The SHPK protein content of fibroblasts homogenates, un-
treated and treated with cyclohexamide for protein stability,
from patient 1 was assessed by Western blot analysis and
compared with a homogenate from control fibroblasts (un-
treated with cyclohexamide). Briefly, washed-cell pellets were
homogenized in radioimmunoprecipitation assay (RIPA) buff-
er, cleared from debris by centrifugation, and 18 μg protein of
each sample was resolved on a 12 % polyacrylamide gel.
After blotting, SHPK protein was detected with a primary
ant ibody against SHPK (ab69920, Abcam Inc.) .
Recombinant human SHPK was used to demonstrate the
Fig. 1 Magnetic resonance imaging (MRI) of patient 1 at the age of 3
years showing a Chiari malformation type 1, ventricular enlargement,
cerebral subcortical atrophy, hyperintense periventricular lesions, and
hypomyelinization
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specificity of the SHPK antibody. Equal protein loading was
indicated by beta actin (A5316, Sigma) detection.
Results
Analysis of erythritol, sedoheptulose, and sedoheptulose-7P
in urine
Strongly elevated excretion of erythritol and sedoheptulose
was detected in both patients, with low-to-normal excretion
of sedoheptulose-7P, biochemically suggesting SHPK defi-
ciency (Table 1).
Molecular analysis gDNA of SHPK and TALDO1
In both patients, a presumed homozygous variant was
detected (patient 1: c.355C > T; p.Arg119X; patient 2:
c.211G > T; p.Glu71X), both predicted to result in trun-
cated nonfunctional proteins. The mother of patient 1 was
found to be a carrier of the same mutation. DNA from the
father was not available for mutational analysis. The par-
ents of patient 2 were both carriers of the variant found in
their daughter. TALDO1 was also sequenced in patient 1
for differential diagnosis, but no pathogenic mutations
were detected.
RNA analysis SHPK
Reverse transcriptase polymerase chain reaction (RT-
PCR) of RNA isolated from blood of the mother of pa-
tient 1 followed by sequencing of the SHPK transcript
showed equal expression of the wild-type allele as that
containing the nonsense mutation. In RNA (cDNA) of
patient 1, only the SHPK transcript containing the non-
sense mutation was detected.
Analysis of SHPK activity in fibroblasts
In fibroblasts from patient 1, strongly reduced formation of
sedoheptulose-7P was detected when compared with control
fibroblasts (2.9 nmol/h/mg protein; controls 20–54), indicat-
ing SHPK deficiency.
SHPK Western blot analysis
We detected no mature SHPK protein in untreated or
cyclohexamide-treated fibroblasts isolated from patient 1. In
contrast, fibroblasts derived from a control individual showed
a prominent SHPK protein content (Fig. 2).
Discussion and conclusions
We present two patients with abnormal sugar and polyol pro-
files (elevated excretion of sedoheptulose and erythritol), sug-
gesting SHPK deficiency.
Clinical presentation in patient 1, with neonatal cholestasis,
hypoglycemia, anemia, and dysmorphism, together with the
biochemical abnormalities of elevated excretion of erythritol
and sedoheptulose, raised the suspicion of TALDO deficiency
(MIM 606003). However, the polyols arabitol and ribitol were
only mildly elevated and sedoheptulose-7P was within the
control range, while in patients with TALDO deficiency,
sedoheptulose-7P in particular is highly elevated.
Patient 2 had a different clinical presentation, with congen-
ital arthrogryposis multiplex, multiple contractures, and
dysmorphisms. She has one healthy, older brother who had a
normal urinary sugar and polyol profile (data not shown).
TALDO deficiency in both patients was ruled out by either
biochemical or DNA studies.
Since SHPK seems to be important in macrophage polari-
zations, we looked for immunological dysfunction in the two
patients with the isolated SHPK deficiency, and although they
are still very young for a complete evaluation, they do not
Table 1 Metabolite concentrations in urine (mmol/mol creatinine) from the two patients with sedoheptulokinase (SHPK) deficiency compared with
age-matched control ranges
Metabolite (mmol/mol creatinine) Patient 1 (1.6 years) Age-matched control
range patient 1
Patient 2 (7 days) Age-matched control
range patient 2
Erythritol 1,045 76–192 2,753 58–162
Arabitol 135 52–88 136 27–97
Ribitol 32 9–24 16 7–16
Sedoheptulose 576 ND–9 253 ND–40
Sedoheptulose-7P < Detection limit (0.02) ND–0.1 < Detection limit (0.05) ND–0.1
Values in bold are above the control range
ND not detectable
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seem to have any obvious immune system dysfunction. SHPK
seems to have a regulating function in glucose metabolism,
contributing to the direct metabolic flux of cellular
sedoheptulose-7P, which is a direct product and substrate of
glucose metabolism. Deficiency of SHPK might therefore in
part contribute to the problems in glycemic control, as seen in
patient 1.
The metabolite profile in both patients was in line with our
findings in cystinosis patients with the 57-kb deletion, includ-
ing SHPK (Wamelink et al 2008). Kardon et al. indicated that
the accumulation of erythritol is likely derived from
sedoheptulose, which—in vitro, at least—can be converted
to sedoheptulose-1-phosphate by fructokinase. The resulting
sedoheptulose-1-phosphate would be converted by aldolase B
to erythrose and dihydroxyacetone–phosphate, and erythrose
would then finally be reduced to erythritol (Kardon et al
2008). Clinical features as described in our patients are not
known in patients with infantile nephropathic cystinosis
caused by the 57-kb deletion (Table 2). In general, infantile
nephropathic cystinosis becomes symptomatic between the
ages of 6 and 12 months, with proximal renal tubulopathy
(renal Fanconi syndrome). Endocrinological, hepatic, gastro-
intestinal, muscular, and neurological abnormalities have also
been described (Nesterova and Gahl WA. Cystinosis 2001).
Mildly altered craniofacial morphology in cystinosis patients
may result in swallowing difficulties and respiratory compli-
cations in the second decade (Bassim et al 2010) of life. Both
of our patients presented neonatally and did not develop renal
tubular Fanconi syndrome.
Isolated SHPK deficiency is confirmed by mutation analy-
sis of the SHPK gene. In each of our two patients, a
(presumed) homozygous nonsense variant (patient 1: c.355C
> T; p.Arg119X; patient 2: c.211G > T; p.Glu71X) was de-
tected, both predicted to result in truncated nonfunctional pro-
teins. Analysis of the SHPK transcript in cells of patient 1 or
the mother showed no signs of nonsense-mediated decay.
However, absence of SHPK protein in patient 1 and the
strongly reduced SHPK activity in fibroblast homogenates
of the patients indicated a severe SHPK deficiency.
The c.355C > T heterozygous allele variant has been de-
tected in 8/4,300 European American and in 0/2,203 African
American control individuals (rs144071313; http://evs.gs.
Fig. 2 Sedoheptulokinase (SHPK) protein expression in untreated and
cyclohexamide (CHX)-treated fibroblast homogenates from patient 1 and
untreated control fibroblasts. Recombinant human SHPK was used to
demonstrate specificity of the SHPK antibody
Table 2 Signs and symptoms of the two patients with sedoheptulokinase (SHPK) deficiency compared with infantile cystinosis and transaldolase
(TALDO) deficiency
Symptoms Patient 1 (3 years) Patient 2 (1 year) Infantile cystinosisa (incl. 57 kb deletion) TALDO deficiency
Anemia + − − +
Cardiac abnormalities − − − +
Contractures − + − −
Delayed puberty ? ? + +/−
Diarrhea + − − −
Facial dysmorphia + + +/− +/−
Failure to thrive + + + +/−
Feeding difficulties − + + (second decade) −
Hypothyrodism − − + +/−
Infectious diseases +/− +/− − −
Liver disease + (neonatal) − + (second decade) +
Neonatal hypoglycemia + − − +/−
Intellectual disability + + − −
Retinopathy − − + −
Rickets − − + +/−
Tubulopathy + (renal failure) − + (Fanconi syndrome) +/−
− Absent, + present, +/− may occur, ? unknown
aNo difference in clinical phenotype between patients with other mutations causing severe infantile nephropathic type or patients with the deletion has
been found (Heil et al 2001)
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washington.edu/EVS/). This relative high frequency of the
heterozygous variant in controls suggests that SHPK
deficiency is more common than currently known or that
homozygosity of this variant is not associated with an inborn
error of metabolism with a severe phenotype. The c.211G > T;
p.Glu71X variant is a novel variant not previously reported.
There remains the question of whether SHPK deficiency is
the causal factor for the clinical phenotypes of our patients.
Although other causes for the clinical presentation were ex-
tensively investigated in both cases, we cannot exclude the
presence of other recessive disorders in these consanguineous
heritages. Since both patients presented very differently and
without a clear clinical overlap with cystinosis patients
(caused by the 57-kb deletion), the biochemical defect of
SHPK deficiency is either unrelated to the clinical phenotypes
or might have a broad phenotypic presentation, which is de-
pendent on external factors and/or the genetic backgrounds of
the individuals. The importance of SHPK as a regulatory en-
zyme has to be further investigated.
With high-throughput sequencing technologies known as
next-generation sequencing (NGS), such as whole-exome
(WES) and whole-genome (WGS) sequencing, more genetic
variants are being detected. These variants have yet to undergo
intensive analysis to determine whether they are indeed clin-
ically relevant. In the past, frameshifts and nonsense muta-
tions were considered pathogenic. This study illustrates that
even if the mutation results in biochemical deficiency, it is
questionable whether this gene is indeed the cause of the dis-
ease. Thus, not only functional studies but also extensive clin-
ical workups are needed.
Clinical relevance of SHPK deficiency is currently un-
known. Identifying other individuals with SHPK deficiency
is needed for further clarification.
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